Utility of electrophysiological studies to predict arrhythmic events  

作　　者：Gabriela Hilfiker Andreas W Schoenenberger Paul Erne Richard Kobza 

机构地区：[1]Division of Cardiology,Luzerner Kantonsspital [2]Division of Geriatrics,Department of General Internal Medicine,Inselspital,Bern University Hospital [3]University of Bern [4]Hirslanden Klinik St Anna

出　　处：《World Journal of Cardiology》2015年第6期344-350,共7页世界心脏病学杂志（英文版）（电子版）

摘　　要：AIM:To evaluate the prognostic value of electrophysiological stimulation(EPS) in the risk stratification for tachyarrhythmic events and sudden cardiac death(SCD).METHODS:We conducted a prospective cohort study and analyzed the long-term follow-up of 265 consecutive patients who underwent programmed ventricular stimulation at the Luzerner Kantonsspital(Lucerne,Switzerland) between October 2003 and April 2012. Patients underwent EPS for SCD risk evaluation because of structural or functional heart disease and/or electrical conduction abnormality and/or after syncope/cardiac arrest. EPS was considered abnormal,if a sustained ventricular tachycardia(VT) was inducible. The primary endpoint of the study was SCD or,in implanted patients,adequate ICD-activation.RESULTS:During EPS,sustained VT was induced in 125 patients(47.2%) and non-sustained VT in 60 patients(22.6%); in 80 patients(30.2%) no arrhythmia could be induced. In our cohort,153 patients(57.7%) underwent ICD implantation after the EPS. During follow-up(mean duration 4.8 ± 2.3 years),a primary endpoint event occurred in 49 patients(18.5%). The area under the receiver operating characteristic curve(AUROC) was 0.593(95%CI:0.515-0.670) for a left ventricular ejection fraction(LVEF) < 35% and 0.636(95%CI:0.563-0.709) for inducible sustained VT during EPS. The AUROC of EPS was higher in the subgroup of patients with LVEF ≥ 35%(0.681,95%CI:0.578-0.785). Cox regression analysis showed that both,sustained VT during EPS(HR:2.26,95%CI:1.22-4.19,P = 0.009) and LVEF < 35%(HR:2.00,95%CI:1.13-3.54,P = 0.018) were independent predictors of primary endpoint events.CONCLUSION:EPS provides a benefit in risk stratificationfor future tachyarrhythmic events and SCD and should especially be considered in patients with LVEF ≥ 35%.AIM:To evaluate the prognostic value of electrophysiological stimulation(EPS) in the risk stratification for tachyarrhythmic events and sudden cardiac death(SCD).METHODS:We conducted a prospective cohort study and analyzed the long-term follow-up of 265 consecutive patients who underwent programmed ventricular stimulation at the Luzerner Kantonsspital(Lucerne,Switzerland) between October 2003 and April 2012. Patients underwent EPS for SCD risk evaluation because of structural or functional heart disease and/or electrical conduction abnormality and/or after syncope/cardiac arrest. EPS was considered abnormal,if a sustained ventricular tachycardia(VT) was inducible. The primary endpoint of the study was SCD or,in implanted patients,adequate ICD-activation.RESULTS:During EPS,sustained VT was induced in 125 patients(47.2%) and non-sustained VT in 60 patients(22.6%); in 80 patients(30.2%) no arrhythmia could be induced. In our cohort,153 patients(57.7%) underwent ICD implantation after the EPS. During follow-up(mean duration 4.8 ± 2.3 years),a primary endpoint event occurred in 49 patients(18.5%). The area under the receiver operating characteristic curve(AUROC) was 0.593(95%CI:0.515-0.670) for a left ventricular ejection fraction(LVEF) &lt; 35% and 0.636(95%CI:0.563-0.709) for inducible sustained VT during EPS. The AUROC of EPS was higher in the subgroup of patients with LVEF ≥ 35%(0.681,95%CI:0.578-0.785). Cox regression analysis showed that both,sustained VT during EPS(HR:2.26,95%CI:1.22-4.19,P = 0.009) and LVEF &lt; 35%(HR:2.00,95%CI:1.13-3.54,P = 0.018) were independent predictors of primary endpoint events.CONCLUSION:EPS provides a benefit in risk stratificationfor future tachyarrhythmic events and SCD and should especially be considered in patients with LVEF ≥ 35%.

关 键 词：Electrophysiologic techniques CARDIAC ARRHYTHMIA SUDDEN CARDIAC DEATH 

分 类 号：R541.7[医药卫生—心血管疾病]